Clinical trials: Vehicle
Dermatitis, Atopic
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
The purpose of this study is to investigate the safety and efficacy of AN2728 Topical Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis.
- Trial name
- NCT02118766
- Testing
- AN2728 Topical Ointment, 2%, Matching vehicle control
- Where
- United States
- Volunteers
- 763 people
- Sponsor
- Pfizer
Dry Eye Disease
Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)
This will be a Phase 3, multicenter, vehicle-controlled, double-masked, randomized study conducted at approximately 20 sites in the United States. All subjects enrolled will have dry eye disease (DED).
- Trial name
- NCT05360966
- Testing
- 0.003% AR-15512 ophthalmic solution, AR-15512 vehicle ophthalmic solution
- Where
- 23 sites in United States
- Volunteers
- 467 people
- Sponsor
- Aerie Pharmaceuticals
Onychomycosis
Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study
A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability of 8-Week Regimens of NVXT topical product in Patients with Mild to Moderate…
- Trial name
- NCT02933879
- Testing
- NVXT topical
- Where
- United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Scars
Safety and Efficacy of SLI-F06 in Wound Healing and Scar Appearance
Multicenter, double-blind study comparing SLI-F06 to vehicle formulation buffer for the improvement in scar appearance and wound strength in routine surgical excisions, as well as post-operative abdominoplasty scar appearance.
- Trial name
- NCT03880058
- Testing
- SLI-F06, Formulation buffer
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Scarless Laboratories, Inc.
Dry Eye Syndrome, Dry Eye
Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye
Thymosin Beta 4 (Tβ4) is a synthetic copy of the naturally-occurring 43-amino acid peptide that is found in a variety of tissues. Tβ4 promotes/accelerates wound repair in dermal, ocular, and cardiac animal models.
- Trial name
- NCT01387347
- Testing
- Thymosin beta 4
- Volunteers
- 72 people
- Sponsor
- ReGenTree, LLC
Acne Vulgaris
A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris
Enrollment of subjects with mild to moderate facial acne. Efficacy was assessed by using an Investigator's Global Assessment scale (IGA 5 point scale) and by counting the number of inflammatory and non-inflammatory lesions on the…
- Trial name
- DFD-03 (NCT03290027)
- Testing
- DFD-03
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
- Trial name
- TRuE-PN2 (NCT05764161)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 76 sites in United States, Australia and 11 more
- Volunteers
- 190 people
- Sponsor
- Incyte Corporation
Extreme Prematurity
Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)
Recombinant human erythropoietin (Epo) is a promising novel neuroprotective agent. Epo decreases neuronal programmed cell death resulting from brain injury; it has anti-inflammatory effects, increases neurogenesis, and protects…
- Trial name
- PENUT (NCT01378273)
- Testing
- Epo, Control
- Where
- 19 sites in United States
- Volunteers
- 941 people
- Sponsor
- University of Washington
Multiple Myeloma
A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma
The primary purpose of this study is to determine the safety and tolerability of SRT501 (5.0 g) with or without concurrent bortezomib administration, when administered once daily in 21 day cycles, in male and female subjects with…
- Trial name
- NCT00920556
- Testing
- 5.0g SRT501, Bortezomib
- Where
- 5 sites in Denmark, United Kingdom
- Volunteers
- 24 people
- Sponsor
- Sirtris, a GSK Company
Heart Failure
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3
This is a double-blind, randomized, two x two crossover (aprepitant vs placebo) during both initiation of Entresto, LCZ696, (50 mg dose) and at steady-state of Entresto (200 mg bid dose or the highest tolerated dose).
- Trial name
- NCT04649229
- Testing
- LCZ 696, Para-aminohippurate, Iohexol
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Yale University
Allergic Conjunctivitis
AGN-229666 for the Treatment of Allergic Conjunctivitis
This study will evaluate the safety and efficacy of AGN-229666 for the treatment of allergic conjunctivitis.
- Trial name
- NCT01754766
- Testing
- AGN-229666, vehicle of AGN-229666
- Where
- Japan
- Volunteers
- 90 people
- Sponsor
- Allergan
Molluscum Contagiosum
Cantharidin Application in Molluscum Patients
This study is a Phase 3, randomized, double-blind, placebo-controlled, pivotal study to evaluate the safety and efficacy of VP-102 topical film-forming solution in subjects with Molluscum Contagiosum.
- Trial name
- CAMP-2 (NCT03377803)
- Testing
- VP-102 - Cantharidin, Topical Film Forming Solution
- Where
- 15 sites in United States
- Volunteers
- 262 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Onychomycosis
Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail
This study will examine the safety, tolerability and efficacy of NVXT in a new formulation in patients with mild-to-moderate fungal infection of the toe nail.
- Trial name
- NCT02343627
- Testing
- NVXT Solution, Vehicle of test product
- Volunteers
- 47 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Meibomian Gland Dysfunction
Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction
Study Design Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel group study Duration: 1 month of TID treatment Treatment Groups, Dosing, and Treatment Regimen Study Treatment: CBT-008 topical…
- Trial name
- NCT05261386
- Testing
- CBT-008
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Cloudbreak Therapeutics, LLC
Corneal Erosion
Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients
The purpose of this study is to measure efficacy and safety with 0.25% SHJ002 sterile ophthalmic solution compared to vehicle in treating corneal erosion in Sjogren's patients.
- Trial name
- NCT06381986
- Testing
- SHJ002, Vehicle
- Where
- 6 sites in Taiwan
- Volunteers
- 116 people
- Sponsor
- Sunhawk Vision Biotech, Inc.
Coping Skills, Family Relations
DWI Offenders and Their Families App for Smartphones
The smart phone application (B-SMART) to be developed in this research project for family members of DWI (Driving While Intoxicated) offenders and offenders themselves will extend the impact of the Ignition Interlock Device (IID)…
- Trial name
- B-SMART (NCT03828370)
- Testing
- B-SMART Intervention Group, Usual and Customary Information Group
- Where
- 2 sites in United States
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- Klein Buendel, Inc.
Raynaud's Phenomenon Secondary to Connective Tissue Disease
Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon
The purpose of this study is to determine the ability of Vascana (0.9% nitroglycerin topical cream) to treat and prevent the symptoms experienced by subject's with Raynaud's Phenomenon.
- Trial name
- NCT02688270
- Testing
- Vascana (0.9% nitroglycerin cream)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Covis Pharma S.à.r.l.
Allergic Conjunctivitis
Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
The purpose of this study is to evaluate the efficacy of loteprednol etabonate ophthalmic base, compared to loteprednol etabonate ophthalmic suspension, and vehicle in the prevention of the signs and symptoms of allergic…
- Trial name
- NCT01107405
- Testing
- Loteprednol etabonate base (QD), Loteprednol etabonate base (BID), Loteprednol etabonate base (QID)
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Bausch & Lomb Incorporated
Tinea Pedis, Athlete's Foot
Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis
This is a study of the safety and efficacy of topical Econazole Nitrate Foam 1% and the foam vehicle in subjects with interdigital tinea pedis (athlete's foot between the toes).
- Trial name
- NCT01353976
- Testing
- Econazole Nitrate Foam 1%, Vehicle Foam
- Where
- 7 sites in United States
- Volunteers
- 264 people
- Sponsor
- AmDerma
Acne Vulgaris
Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne
An exploratory Phase 2, single, centre, prospective, randomized, placebo-controlled, double-blinded, split-pace (left/right) design trial to evaluate the efficacy and tolerability of LEO 43204 in adults with moderate to severe…
- Trial name
- NCT02575950
- Testing
- LEO43204
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- LEO Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.